What it's for (Indications)
- Chloramphenicol is a broad-spectrum antibiotic indicated for the treatment of serious infections for which less toxic antimicrobial agents are ineffective or contraindicated.
- Its use is reserved for conditions where its potential benefits outweigh the significant risks of severe adverse effects.
- Primary indications include severe invasive infections such as typhoid fever (due to susceptible Salmonella species), bacterial meningitis (caused by Haemophilus influenzae, Streptococcus pneumoniae, or Neisseria meningitidis) in penicillin-allergic patients, rickettsial infections (e.
- g.
- , Rocky Mountain spotted fever, typhus), and specific anaerobic infections, particularly in central nervous system abscesses.
- It is also used in specific eye and ear infections topically, but the systemic use is strictly limited due to its severe toxicity profile.
- Careful culture and susceptibility testing should guide its use.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Systemic chloramphenicol dosage must be carefully individualized based on the patient's age, weight, renal and hepatic function, and the severity of the infection. For adults, the typical oral or intravenous dose is 50 mg/kg/day in divided doses every 6 hours, which may be increased to 100 mg/kg/day in very severe infections like meningitis, under close monitoring. The maximum recommended dose should generally not exceed 4 grams per day. In pediatric patients, particularly neonates and premature infants, extreme caution is warranted due to the risk of 'Gray Baby Syndrome.' Neonatal dosing often starts at 25 mg/kg/day in divided doses, with close monitoring of serum concentrations. Dose adjustments are critical in patients with impaired hepatic or renal function to prevent accumulation and toxicity. Therapeutic drug monitoring (TDM) of serum chloramphenicol levels is highly recommended, aiming for peak levels between 10-20 mcg/mL and trough levels below 10 mcg/mL, especially during prolonged therapy or in patients with compromised organ function to minimize toxicity while ensuring efficacy. |
Safety & Warnings
Common Side Effects
- Chloramphenicol is associated with a range of adverse effects, some of which are severe and potentially fatal.
- The most critical include dose-related and non-dose-related hematological toxicities.
- Dose-related bone marrow suppression manifests as anemia, leukopenia, and thrombocytopenia, which is generally reversible upon discontinuation.
- However, the non-dose-related, idiosyncratic aplastic anemia is rare but often fatal, and can occur weeks or months after cessation of therapy, often without warning.
- Gastrointestinal side effects include nausea, vomiting, diarrhea, glossitis, stomatitis, and enterocolitis.
- Neurological adverse effects can occur, particularly with prolonged high-dose therapy, and include peripheral neuritis, optic neuritis (which may lead to blindness), and headache.
- Hypersensitivity reactions such as fever, rash, angioedema, and Jarisch-Herxheimer reactions have been reported.
- A unique and severe toxicity in neonates and premature infants is 'Gray Baby Syndrome,' characterized by vomiting, abdominal distension, lethargy, flaccidity, hypothermia, ashen gray cyanosis, and progressive cardiovascular collapse, often leading to death.
- This syndrome is due to inadequate hepatic glucuronidation and renal excretion of the drug, leading to toxic accumulation.
Serious Warnings
- Black Box Warning: **WARNING: SERIOUS AND FATAL BLOOD DYSCRASIAS** Chloramphenicol is associated with serious and fatal blood dyscrasias, including aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia. This drug should not be used in the treatment of trivial infections or where it is not indicated, as the potential serious adverse effects outweigh the benefit. Irreversible and fatal aplastic anemia is a rare but critical adverse reaction, which may occur after short-term or prolonged therapy, and may be delayed for weeks or months after cessation of treatment. There is no certainty that monitoring blood counts will prevent this complication, but complete blood counts (CBC) with differential should be performed frequently (e.g., every 2 days) during therapy. All patients should be advised to report immediately any symptoms such as fever, sore throat, or unusual bleeding or bruising. The use of chloramphenicol is reserved for serious infections where other less toxic antibiotics are ineffective or contraindicated. This medication also carries a significant risk of 'Gray Baby Syndrome' in neonates, particularly premature infants, due to their inability to adequately metabolize and excret the drug, leading to accumulation and circulatory collapse.
- Chloramphenicol carries significant warnings due to its severe potential for adverse effects.
- Due to the risk of fatal blood dyscrasias, it should only be used in serious infections for which less toxic antibiotics are ineffective or contraindicated.
- Bone marrow toxicity can manifest in two forms: a reversible, dose-related bone marrow suppression (anemia, leukopenia, thrombocytopenia) and an irreversible, idiosyncratic aplastic anemia, which is rare but often fatal.
- Aplastic anemia can occur after short-term or prolonged therapy and may be delayed for weeks or months after treatment cessation.
- Complete blood counts (CBC) with differential should be performed frequently (e.
- g.
- , every 2 days) during therapy.
- Patients should be warned about the symptoms of blood disorders (e.
- g.
- , fever, sore throat, bruising, unusual bleeding) and advised to seek immediate medical attention if these occur.
- 'Gray Baby Syndrome' is a critical concern in neonates and premature infants due to their underdeveloped metabolic pathways; chloramphenicol use in this population requires extreme caution, meticulous dosing, and therapeutic drug monitoring.
- Prolonged therapy may lead to optic and peripheral neuritis.
- Superinfections with non-susceptible organisms, including fungi, can occur with prolonged use.
- It should be used with caution in patients with hepatic or renal impairment, and dosage adjustments are imperative to prevent accumulation and toxicity.
How it Works (Mechanism of Action)
Chloramphenicol exerts its bacteriostatic effect by inhibiting bacterial protein synthesis. It achieves this by reversibly binding to the 50S ribosomal subunit of susceptible bacteria. This binding prevents the peptidyl transferase enzyme from forming peptide bonds between amino acids, thereby blocking the elongation of the polypeptide chain during protein synthesis. The specific binding site overlaps with those of macrolides and clindamycin, leading to potential competitive inhibition if used concurrently. Chloramphenicol is a broad-spectrum antibiotic, effective against a wide range of Gram-positive and Gram-negative bacteria, as well as anaerobic organisms, Rickettsiae, and Chlamydiae. Its ability to penetrate tissues, including the central nervous system and cerebrospinal fluid, is a significant pharmacological advantage for treating specific severe infections in these sites. However, this broad-spectrum activity and excellent tissue penetration are balanced by its severe toxicity profile, necessitating its restricted use.